PDS Biotechnology Corporation
NASDAQ
Closed
Aug 11, 2026
Day's Range
0.233752 wk Range
0.2337Key Statistics
Symbol
PDSB
Name
PDS Biotechnology Corporation
Currency
USD
Exchange
NASDAQ
High
0.6222
Low
0.2337
Open
‪0.6201‬
Last
‪0.2551‬
Market Cap
40.88M
Pe Ratio
‪-0.32‬
Volume
281.43K
Average Volume
222.62K
Dividend Yield
‪0.00%‬
Change
-0.48
Percent Change
-65.11
Timestamp
2026-08-11
Close
0.2551
Today Range Start
‪0.2337‬
Today Range End
‪0.6222‬
52 Week Range Start
‪0.2337‬
52 Week Range End
‪1.55‬
Type
Stocks
Country
United States
Compliance - PDSB - PDS Biotechnology Corporation
Compliance
Status
NON_COMPLIANT
Report Date
2025-02-16
Business Screen
NON_COMPLIANT
Financial Screen
COMPLIANT
Compliant Revenue
‪80.00%‬
Non Compliant Revenue
‪12.00%‬
Questionable Revenue
‪8.00%‬
Securities To Market Cap Ratio
‪1.00%‬
Debt To Market Cap Ratio
‪3.00%‬
Historical Data - PDSB - PDS Biotechnology Corporation
Historical Data
Market Cap - PDSB - PDS Biotechnology Corporation
Market Cap
2026-08-10
40.88M
2026-08-07
43.35M
2026-08-06
41.77M
2026-08-05
40.63M
2026-08-04
40.26M
2026-08-03
39.95M
2026-07-31
38.36M
2026-07-30
39.08M
2026-07-29
37.44M
2026-07-28
38.61M
Splits - PDSB - PDS Biotechnology Corporation
Splits
2019-03-18
1-for-20 split (20)
Earnings - PDSB - PDS Biotechnology Corporation
Earnings
Balance Sheet - PDSB - PDS Biotechnology Corporation
Balance Sheet
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
 Assets | 30.49M | 45.35M | 59.39M | 77M | 67.19M | 30.89M |
| Liabilities | 21.24M | 26.35M | 33.25M | 33M | 3.98M | 3.76M |
| Shareholders Equity | 9.25M | 19M | 26.13M | 44M | 63.21M | 27.12M |
Cash Flow - PDSB - PDS Biotechnology Corporation
Cash Flow
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Operating Activities | - | - | - | - | - | - |
| Investing Activities | - | - | - | - | - | - |
| Financing Activities | - | - | - | - | - | - |
| End Cash Position | 26.71M | 41.68M | 56.56M | 73.82M | 65.24M | 28.83M |
| Income Tax Paid | - | - | - | - | - | - |
| Interest Paid | 2.92M | 3.55M | 3.53M | 852.22K | 0 | - |
| Free Cash Flow | -27.75M | -35.05M | -33.63M | -25.70M | -12.48M | -13.14M |
Income Statement - PDSB - PDS Biotechnology Corporation
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expense | - | - | - | - | - | - |
| Operating Income | -31.54M | -36.32M | -43.04M | -41.67M | -21.43M | -14.90M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | - | - | - | - | - | - |
| Pre Tax Income | -35.66M | -38.47M | -44.34M | -42.05M | -21.43M | -14.84M |
| Income Tax | -1.16M | -869.16K | -1.40M | -1.19M | -4.51M | 0 |
| Net Income | -34.49M | -37.61M | -42.94M | -40.85M | -16.91M | -14.84M |
| EPS Basic | -0.74 | -1.03 | -1.39 | -1.43 | -0.66 | -0.89 |
| EPS Diluted | -0.74 | -1.03 | -1.39 | -1.43 | -0.66 | -0.89 |
| Basic Shares Outstanding | 46.38M | 36.45M | 30.95M | 28.59M | 25.59M | 16.74M |
| Diluted Shares Outstanding | 46.38M | 36.45M | 30.95M | 28.59M | 25.59M | 16.74M |
| Ebit | -30.32M | -33.80M | -40.14M | -40.73M | -21.43M | -14.90M |
| Ebitda | -30.30M | -33.78M | -40.12M | -40.73M | -21.42M | -14.88M |
| Net Income Continuous Operations | -34.49M | -37.61M | -42.94M | -40.85M | -16.91M | -14.84M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
Recommendations - PDSB - PDS Biotechnology Corporation
Recommendations
Profile - PDSB - PDS Biotechnology Corporation
Profile
Mic Code
XNCM
Sector
Healthcare
Industry
Biotechnology
Employees
24
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies. The primary function of PDS Biotechnology is to harness the power of the immune system to eradicate cancer cells, leveraging its proprietary Versamune platform technology. This innovative approach aims to enhance the delivery and presentation of antigens to the immune system, thereby stimulating a potent and targeted immune response against tumors. PDS Biotechnology is deeply integrated into the healthcare and biotechnology sectors, particularly impacting the development of therapies for various types of cancer, including head and neck, anal, and cervical cancers, as well as other oncology indications. As a significant player in the field of immuno-oncology, PDS Biotechnology contributes to advancing cancer treatment options by focusing on safer and more efficient therapeutic vaccines and combines cutting-edge science with clinical applications to potentially improve patient outcomes. Its commitment to innovation positions the company as a critical driver of progress in next-generation cancer therapies within the financial market.
Profile Details
Type
Common Stock
Ceo
Dr. Frank K. Bedu-Addo Ph.D.
Address
303A College Road East
City
Princeton
State
NJ
Zip
08540
Country
United States
Phone
800 208 3343
